Evaluation of Aflatoxin M1 Effects on the Metabolomic and Cytokinomic Profiling of a Hepatoblastoma Cell Line

Silvia Marchese, Angela Sorice, Andrea Ariano, Salvatore Florio, Alfredo Budillon, Susan Costantini, Lorella Severino

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Hepatoblastoma incidence has been associated with different environmental factors even if no data are reported about a correlation between aflatoxin exposure and hepatoblastoma initiation. Considering that hepatoblastoma develops in infants and children and aflatoxin M1 (AFM1), the aflatoxin B1 (AFB1) hydroxylated metabolite, can be present in mothers' milk and in marketed milk products, in this study we decided to test the effects of AFM1 on a hepatoblastoma cell line (HepG2). Firstly, we evaluated the effects of AFM1 on the cell viability, apoptosis, cell cycle, and metabolomic and cytokinomic profile of HepG2 cells after treatment. AFM1 induced: (1) a decrease of HepG2 cell viability, reaching IC50 at 9 µM; (2) the blocking of the cell cycle in the G0/G1 phase; (3) the decrease of formiate levels and incremented level of some amino acids and metabolites in HepG2 cells after treatment; and (4) the increase of the concentration of three pro-inflammatory cytokines, IL-6, IL-8, and TNF-α, and the decrease of the anti-inflammatory interleukin, IL-4. Our results show that AFM1 inhibited the growth of HepG2 cells, inducing both a modulation of the lipidic, glycolytic, and amino acid metabolism and an increase of the inflammatory status of these cells.

Original languageEnglish
JournalToxins
Volume10
Issue number11
DOIs
Publication statusPublished - Oct 28 2018

Fingerprint

Aflatoxin M1
Hepatoblastoma
Metabolomics
Hep G2 Cells
Cells
Cell Line
Metabolites
Interleukin-4
Cell Survival
Cell Cycle
Milk
Amino Acids
Cell Cycle Resting Phase
Aflatoxin B1
Aflatoxins
Interleukins
G1 Phase
Interleukin-8
Metabolism
Inhibitory Concentration 50

Keywords

  • aflatoxin M1
  • cytokinome
  • hepatoblastoma
  • metabolome

ASJC Scopus subject areas

  • Toxicology
  • Health, Toxicology and Mutagenesis

Cite this

Evaluation of Aflatoxin M1 Effects on the Metabolomic and Cytokinomic Profiling of a Hepatoblastoma Cell Line. / Marchese, Silvia; Sorice, Angela; Ariano, Andrea; Florio, Salvatore; Budillon, Alfredo; Costantini, Susan; Severino, Lorella.

In: Toxins, Vol. 10, No. 11, 28.10.2018.

Research output: Contribution to journalArticle

Marchese, Silvia ; Sorice, Angela ; Ariano, Andrea ; Florio, Salvatore ; Budillon, Alfredo ; Costantini, Susan ; Severino, Lorella. / Evaluation of Aflatoxin M1 Effects on the Metabolomic and Cytokinomic Profiling of a Hepatoblastoma Cell Line. In: Toxins. 2018 ; Vol. 10, No. 11.
@article{e53fbf26e920455787a9b637ebc5c7a8,
title = "Evaluation of Aflatoxin M1 Effects on the Metabolomic and Cytokinomic Profiling of a Hepatoblastoma Cell Line",
abstract = "Hepatoblastoma incidence has been associated with different environmental factors even if no data are reported about a correlation between aflatoxin exposure and hepatoblastoma initiation. Considering that hepatoblastoma develops in infants and children and aflatoxin M1 (AFM1), the aflatoxin B1 (AFB1) hydroxylated metabolite, can be present in mothers' milk and in marketed milk products, in this study we decided to test the effects of AFM1 on a hepatoblastoma cell line (HepG2). Firstly, we evaluated the effects of AFM1 on the cell viability, apoptosis, cell cycle, and metabolomic and cytokinomic profile of HepG2 cells after treatment. AFM1 induced: (1) a decrease of HepG2 cell viability, reaching IC50 at 9 µM; (2) the blocking of the cell cycle in the G0/G1 phase; (3) the decrease of formiate levels and incremented level of some amino acids and metabolites in HepG2 cells after treatment; and (4) the increase of the concentration of three pro-inflammatory cytokines, IL-6, IL-8, and TNF-α, and the decrease of the anti-inflammatory interleukin, IL-4. Our results show that AFM1 inhibited the growth of HepG2 cells, inducing both a modulation of the lipidic, glycolytic, and amino acid metabolism and an increase of the inflammatory status of these cells.",
keywords = "aflatoxin M1, cytokinome, hepatoblastoma, metabolome",
author = "Silvia Marchese and Angela Sorice and Andrea Ariano and Salvatore Florio and Alfredo Budillon and Susan Costantini and Lorella Severino",
year = "2018",
month = "10",
day = "28",
doi = "10.3390/toxins10110436",
language = "English",
volume = "10",
journal = "Toxins",
issn = "2072-6651",
publisher = "Multidisciplinary Digital Publishing Institute (MDPI)",
number = "11",

}

TY - JOUR

T1 - Evaluation of Aflatoxin M1 Effects on the Metabolomic and Cytokinomic Profiling of a Hepatoblastoma Cell Line

AU - Marchese, Silvia

AU - Sorice, Angela

AU - Ariano, Andrea

AU - Florio, Salvatore

AU - Budillon, Alfredo

AU - Costantini, Susan

AU - Severino, Lorella

PY - 2018/10/28

Y1 - 2018/10/28

N2 - Hepatoblastoma incidence has been associated with different environmental factors even if no data are reported about a correlation between aflatoxin exposure and hepatoblastoma initiation. Considering that hepatoblastoma develops in infants and children and aflatoxin M1 (AFM1), the aflatoxin B1 (AFB1) hydroxylated metabolite, can be present in mothers' milk and in marketed milk products, in this study we decided to test the effects of AFM1 on a hepatoblastoma cell line (HepG2). Firstly, we evaluated the effects of AFM1 on the cell viability, apoptosis, cell cycle, and metabolomic and cytokinomic profile of HepG2 cells after treatment. AFM1 induced: (1) a decrease of HepG2 cell viability, reaching IC50 at 9 µM; (2) the blocking of the cell cycle in the G0/G1 phase; (3) the decrease of formiate levels and incremented level of some amino acids and metabolites in HepG2 cells after treatment; and (4) the increase of the concentration of three pro-inflammatory cytokines, IL-6, IL-8, and TNF-α, and the decrease of the anti-inflammatory interleukin, IL-4. Our results show that AFM1 inhibited the growth of HepG2 cells, inducing both a modulation of the lipidic, glycolytic, and amino acid metabolism and an increase of the inflammatory status of these cells.

AB - Hepatoblastoma incidence has been associated with different environmental factors even if no data are reported about a correlation between aflatoxin exposure and hepatoblastoma initiation. Considering that hepatoblastoma develops in infants and children and aflatoxin M1 (AFM1), the aflatoxin B1 (AFB1) hydroxylated metabolite, can be present in mothers' milk and in marketed milk products, in this study we decided to test the effects of AFM1 on a hepatoblastoma cell line (HepG2). Firstly, we evaluated the effects of AFM1 on the cell viability, apoptosis, cell cycle, and metabolomic and cytokinomic profile of HepG2 cells after treatment. AFM1 induced: (1) a decrease of HepG2 cell viability, reaching IC50 at 9 µM; (2) the blocking of the cell cycle in the G0/G1 phase; (3) the decrease of formiate levels and incremented level of some amino acids and metabolites in HepG2 cells after treatment; and (4) the increase of the concentration of three pro-inflammatory cytokines, IL-6, IL-8, and TNF-α, and the decrease of the anti-inflammatory interleukin, IL-4. Our results show that AFM1 inhibited the growth of HepG2 cells, inducing both a modulation of the lipidic, glycolytic, and amino acid metabolism and an increase of the inflammatory status of these cells.

KW - aflatoxin M1

KW - cytokinome

KW - hepatoblastoma

KW - metabolome

UR - http://www.scopus.com/inward/record.url?scp=85055613279&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85055613279&partnerID=8YFLogxK

U2 - 10.3390/toxins10110436

DO - 10.3390/toxins10110436

M3 - Article

C2 - 30373285

AN - SCOPUS:85055613279

VL - 10

JO - Toxins

JF - Toxins

SN - 2072-6651

IS - 11

ER -